Jiangsu Nhwa Pharmaceutical Co Ltd

NHWA Pharmaceutical announced that its Class 1 chemical drug NH302 Injection has obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, and will proceed with clinical trials. NH302 is a peripherally selective Kappa receptor agonist. Preclinical studies have shown that it has strong agonistic activity on the Kappa receptor and demonstrated good analgesic effects in multiple animal pain models, making it a potential treatment for acute pain. In the first half of 2026, NHWA Pharmaceutical achieved revenue of 3.218 billion yuan and net profit attributable to the parent of 741 million yuan.

Nhua Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 741 million yuan, up 5.74% from the same period last year. Total operating revenue was 3.218 billion yuan, up 6.91% year-on-year, marking five consecutive years of growth. Net cash inflow from operating activities was 280 million yuan, down 43.33% year-on-year. The company's latest asset-liability ratio was 12.30%, gross margin was 73.86%, and diluted earnings per share was 0.73 yuan.

Nhua Pharmaceutical released its 2026 half-year report. Net profit attributable to the parent in the first half was 741 million yuan, up 5.7% year on year. Operating revenue was 3.218 billion yuan, up 6.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 746 million yuan, up 6.7% year on year. Net operating cash flow was 280 million yuan, down 43.3% year on year. Second-quarter operating revenue was 1.61 billion yuan, up 7.3% year on year, and net profit attributable to the parent was 423 million yuan, up 5.9% year on year. The company said its main business is pharmaceutical research and development, production and sales. In particular, it maintained stability in central nervous system products, increased research and development investment, and advanced the layout of its new product pipeline.

Nhua Pharmaceutical disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 3.218 billion yuan, up 6.91% year on year. Net profit attributable to shareholders of the listed company was 741 million yuan, up 5.74% year on year. Net profit attributable to shareholders after deducting non-recurring items was 746 million yuan, up 6.65% year on year. By business segment, anesthetic products generated revenue of 1.668 billion yuan, up 2.08% year on year. Psychiatric products generated revenue of 651 million yuan, up 4.88% year on year. Neurological product revenue reached 222 million yuan, up 33.70% year on year, making it the fastest-growing core business segment in the first half. Commercial pharmaceutical business revenue in the same period reached 461 million yuan, up 17.20% year on year. The company invested 385 million yuan in research and development in the first half, with more than 70 projects under study, including over 20 innovative drug projects and more than 40 key generic drug projects, while also carrying out 5 consistency evaluation projects. Its self-developed Class 1 innovative drug NH600001 emulsion injection has been submitted for marketing approval and passed the registration inspection by the National Medical Products Administration. The Class 1 innovative drug NHL35700 for schizophrenia entered Phase III clinical trials in June this year. NH102 tablets, YH1910-Z02 injection, and YH1910-Z01 nasal spray have completed Phase II clinical studies, and NH130 tablets are currently undergoing Phase II clinical research. The company has also established an AI-driven research and development team and is laying out antibody-oligonucleotide conjugate technology. Its investee company Jiangsu Haoxinqing's internet hospital has registered more than 80,000 doctors. The C-BCT digital cognitive assessment product of its controlling subsidiary Beijing Yihua has established cooperation with more than 100 medical institutions and has served over 300,000 patient visits cumulatively.